GlassScriptPhysician profile
Thomas B Thomason
NPI 1396895835
$2,748.51
in general payments reported to CMS, 2019-2025
21 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.68 · 2020: $204 · 2021: $239 · 2022: $507 · 2023: $341 · 2024: $912 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107 · Debt Forgiveness: $571 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.46 |
| Debt Forgiveness | $571.43 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $688.22 | 2020-2025 | |
| Photonicare INC | $571.43 | 2024 | Otosight Middle Ear Scope |
| Glaxosmithkline, LLC. | $291.15 | 2021-2025 | Nucala |
| Aerin Medical INC. | $268.71 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $144.98 | 2020-2024 | Dupixent |
| Stryker Corporation | $117.00 | 2020-2025 | Audion Et Dilation System |
| Alk-Abello, INC | $94.75 | 2020-2022 | |
| Optinose US, INC. | $80.37 | 2019-2023 | |
| Integra Lifesciences Corporation | $67.33 | 2019-2022 | |
| Intersect Ent, INC. | $65.89 | 2019-2021 | |
| Medtronic, INC. | $56.02 | 2024 | Propel |
| Acclarent, INC | $54.07 | 2019-2023 | Trudi Nav Cable |
| Sanofi-Aventis U.S. LLC | $52.99 | 2023 | |
| Merck Sharp & Dohme LLC | $48.88 | 2023-2025 | Keytruda |
| Inspire Medical Systems, INC. | $32.14 | 2024 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $30.53 | 2022-2023 | Grafix Pl |
| Amgen INC. | $23.66 | 2025 | Tezspire |
| Organogenesis INC. | $22.52 | 2024 | |
| Hikma Pharmaceuticals USA | $16.48 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $15.36 | 2025 | Xhance |
| Phathom Pharmaceuticals, INC. | $6.03 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.